Vessi Medical

Vessi Medical announced today that it closed a Series A financing round worth $16.5 million to support its cryotherapy technology.

Misgav, Israel-based Vessi develops its technology to treat non-muscle invasive bladder cancer (NMIBC). It could provide a therapeutic alternative to transurethral resection of bladder tumor (TURBT), the current first-line therapy. Vessi believes its bladder-specific, proprietary cryotherapy could significantly improve patients’ quality of life. It’s already been successfully used in a first-in-human study.

An undisclosed global strategic investor, ALIVE-Isreal HealthTech Fund and Agriline led the funding round. They joined The Trendlines Group as investors in Vessi Medical. While the company didn’t list the intended use of proceeds, ALIVE Managing General Partner Rafi Beyar said in a news release that the funds allow Vessi’s team “to focus on executing its clinical and regulatory plan, and efficiently …

Vessi Medical announced today that it raised $1.7 million in funding for its cryoablation treatment for superficial bladder cancer.

Agriline, the Trendlines Group, the Israel Innovation Authority and ExitValley investors all participated in the financing round to support the minimally invasive treatment, according to a news release.

Misgav, Israel-based Vessi Medical touts its cryoablation solution, which applies to superficial bladder cancer or non-muscle invasive bladder cancer (NMIBC), as capable of improving quality of life for those suffering from symptoms including urination problems, pain and blood in urine, along with sexual dysfunction, mental health effects and general low quality of life.

The Vessi system includes a standalone console and a disposable device inserted transurethrally into the bladder. The company is planning a first-in-human study for the first quarter of 2021.

“Demonstrating the technology in humans is an importan…